Predictive Oncology (POAI) Corporate Media Kit

Leadership Team Dr. Carl Schwartz Interim President, Chief Executive Officer and Board of Directors – Predictive Oncology Dr. Schwartz holds BA and DDS degrees from the University of Detroit and grew a single dental practice into 14 offices by the time he left dentistry to join a family business in 1988. As CEO of Plastics Research Corporation, a specialty manufacturer of structural foam molding, he led company growth from $2 million in revenues and 20 employees to become the largest manufacturer of structural foam molding products under one roof in the countrywith more than $60 million in revenues and 300 employees. From a board appointment to Skyline Medical in 2016, Dr. Schwartz began making his vision of personalized medicine a reality. TumorGenesis was formed as a subsidiary in 2018 and Helomics was acquired in 2019. The syner- gistic and complementary companies form the basis of Predictive Oncology and represent a paradigm shift in in the predictive models needed for effective precision medicine. Bob Myers Chief Financial Officer, Predictive Oncology CFO Bob Myers has extensive experience spanning over 30 years focused on medical device services and manufacturing across mul- tiple industries. The majority of his career has been dedicated to financial leadership roles, serving as a CFO and controller. Myers holds an MBA in finance from Adelphi University, as well as a BBA in public accounting from Hofstra University.